Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to placebo
The safety profile of sibeprenlimab was favorable and consistent with previously reported data
Immunoglobulin A nephropathy is a progressive, immune-mediated, chronic kidney disease that can lead to end-stage kidney disease (ESKD) over the lifetime of most patients under current optimized standard care
Sibeprenlimab filed its Biologics License Application (BLA) and received Priority Review designation from the U.S. Food and Drug Administration (FDA) with a target action date of November 28th, 2025
PRINCETON, N.J. & TOKYO, June 06, 2025--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group.1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo.
Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals2.
Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home.
"We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials," said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. "Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease."
The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN1.
"The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology," said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. "The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN."
About the VISIONARY Study
The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months1.
About Sibeprenlimab
Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss.
About IgAN and APRIL
IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients9,10,11.
IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5.
APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys5.
About Otsuka
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024.
All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at https://www.otsuka.co.jp/en/.
About Visterra
Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit www.visterrainc.com.
References
Otsuka Pharmaceutical Development & Commercialization, Inc.Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN). Clinicaltrials.gov. https://www.nejm.org/doi/full/10.1056/NEJMoa2305635
Thompson A, Carroll K, Inker LA, et al. Proteinuria Reduction as a Surrogate End Pointin Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469-481.doi:10.2215/CJN.08600718
Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022;7(5):993-1003.
Chang S, Li XK. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy (nih.gov)
Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and April in IGA nephropathy: Pathogenic mechanisms and targeted therapies. Frontiers in nephrology. February 1, 2024.
Mathur M, Barratt J, Chacko B, et al. A Phase 2 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy Patients. NEJM. 2023 https://www.nejm.org/doi/full/10.1056/NEJMoa2305635
Gharavi, Ali G, et al. "Aberrant Iga1 Glycosylation Is Inherited in Familial and Sporadic IGA Nephropathy." Journal of the American Society of Nephrology : JASN, U.S. National Library of Medicine, May 2008, pmc.ncbi.nlm.nih.gov/articles/PMC2386728
Kant, Sam, et al. "Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review - American Journal of Kidney Diseases." American Journal of Kidney Diseases, Apr. 2022, www.ajkd.org/article/S0272-6386(21)00835-0/fulltext.
Pitcher, D. Braddon, et. al Long-term outcomes in IGA nephropathy. Clinical journal of the American Society of Nephrology : CJASN. https://pubmed.ncbi.nlm.nih.gov/37055195/.
Lai K. Iga nephropathy. Nature reviews. Disease primers. 2016
Cheung, Chee Kay & Boyd, JKF & Feehally, J.. (2012). Evaluation and management of IgA nephropathy. Clinical Medicine. 12. s27-s30. 10.7861/clinmedicine.12-6-s27.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250606873555/en/
Contacts
Contacts for Media
Otsuka in the U.S.
Robert MurphyCorporate CommunicationsOtsuka America Pharmaceutical, Inc.robert.murphy@otsuka-us.com
+1 609 249 7262
Otsuka in Japan
Jeffrey GilbertLeader, Pharmaceutical PROtsuka Pharmaceutical Co., Ltd.gilbert.jeffrey.a@otsuka.jp
+81 3 6361 7379
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Food recall: Brown eggs sold at grocery stores across California have salmonella risk
A California company is recalling 1.7 million cartons of brown eggs — sold at stores including Walmart in nine states including California — because the eggs may be contaminated with salmonella bacteria. August Egg Company of Hilmar is recalling 1,700,000 dozen brown cage-free and brown certified organic eggs for potential salmonella risk. The eggs were distributed over the last four months, some with sell by dates as late as June 19, according to the recall notice from the Food and Drug Administration. The eggs are linked to an ongoing Salmonella Enteritidis outbreak in seven states, in which 79 people have been sickened and at least 21 hospitalized, but no deaths have been reported, according to the Centers for Disease Control and Prevention. Most of the people sickened (63) live in California, according to the CDC. Nevada and Washington reported four illnesses each, with additional cases in Arizona (3), New Jersey (2), Nebraska (2), Kentucky (1). Ill people in Kentucky, New Jersey, and Washington reported traveling to California and Nevada before they got sick. Most of those sickened (90%) reported eating eggs, the CDC said. Some samples taken by the FDA during an inspection at August Egg Company's processing facility tested positive for the strain of salmonella similar to those related to the persons sickened in the outbreak, the CDC said. August Egg Co. said its internal food safety team is conducting its own investigation to "identify what measures can be established to prevent this situation from recurring," the company said in a statement accompanying the recall. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." USA TODAY Recall Database: Search vehicle, product and food recalls The recalled eggs were distributed beginning Feb. 3 across multiple retailers in nine states: Eggs with sell-by dates to June 4: Through May 15, eggs with those sell-by dates were distributed to Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs stores in California and Nevada. Eggs with sell-by dates to June 19: Through May 6, eggs with those sell-by dates were distributed to Walmart locations in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. August Egg Co. said consumers can identify the recalled eggs by the plant code on one side of the egg carton. They can return the eggs to the place of purchase for a refund. Consumers with questions can call the company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Here's the products recalled with plant code and UPC. Salmonella causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms of salmonella infection – including diarrhea, fever and stomach cramps – typically arise six hours to six days after exposure and may last 4 to 7 days. Severe infections can also include aches, headaches, elevated fever, lethargy, rashes, and blood in the urine or stool. Salmonella poisoning, also known as salmonellosis, is a common gastrointestinal infection in California, with about 5,000 confirmed cases annually, according to the California Department of Public Health. The Centers for Disease Control estimates that around 3,000 people die from a foodborne illness, and of those about 420 people die from Salmonella infections. This article originally appeared on Palm Springs Desert Sun: Egg recall 2025: Salmonella risk for eggs sold at California stores
Business Upturn
2 hours ago
- Business Upturn
Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management
New York, June 07, 2025 (GLOBE NEWSWIRE) — Ro Weight Loss, a digital health service from Roman Health Ventures Inc., has updated its official website to provide new information about its medically-guided weight management program. Designed for adults across the United States, the offering connects eligible individuals with licensed healthcare providers through a secure telehealth platform. According to the official website ( Ro Weight Loss offers a structured approach to weight care, including FDA-approved treatment options when appropriate, along with personalized clinical support and lifestyle guidance. The service is designed to be accessible from home and does not require in-person clinic visits or restrictive dietary regimens. 'We created Ro Weight Loss to make effective, evidence-backed care more accessible,' said a Ro spokesperson. 'Our platform empowers people with a personalized plan, clinical oversight, and flexible support tailored to their health goals.' Ro states that the program prioritizes safety, transparency, and sustainable progress. After completing an online health assessment, users may be evaluated by board-certified providers to determine medical eligibility. When appropriate, providers may prescribe treatment as part of a comprehensive plan that includes coaching and follow-up. All care is delivered by licensed professionals, and medications are dispensed by U.S.-based pharmacies. The platform supports discreet access to care, ongoing communication with providers, and convenience for users managing their health goals remotely. The Ro Weight Loss program is currently available in all 50 states. Individuals interested in exploring eligibility or learning more about the service can visit the official website for additional information. About Ro Weight Loss Ro Weight Loss is a service provided by Roman Health Ventures Inc., a New York-based telehealth company offering evidence-based treatment across multiple areas of care, including weight management, mental health, dermatology, and more. Ro's digital platform empowers individuals to receive safe, personalized healthcare from the comfort of home. Product and Contact Information Brand: Ro Weight Loss Website: Email: [email protected] Mailing Address:Roman Health Ventures Inc.625 6th Ave, 4th Floor New York, NY 10011
Yahoo
2 hours ago
- Yahoo
Egg brands sold in Washington recalled, CDC warning of Salmonella outbreak
The U.S. Centers for Disease Control and Prevention (CDC) is warning of a Salmonella outbreak linked to several brands of eggs sold in nine states, including Washington. Seventy-nine people in seven states have contracted Salmonella linked to the same outbreak strain found in the eggs, the CDC says. The August Egg Company, based in Hilmar, California, has issued a recall of 1,700,000 dozen eggs sold at Walmart locations in Washington, according to the CDC. In a release, the CDC says twenty-one people have been hospitalized with Salmonella, and no deaths have been reported. The eggs were sold to retailers and restaurants in Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington, and Wyoming, the CDC says. The shell eggs were distributed from February 3 through May 6, with sell-by dates from March 4 to June 19, according to the Food and Drug Administration (FDA). In a release, the FDA says brands sold include: Clover Organic Large Brown Eggs O Organics Large Brown Eggs Marketside Organic Large Cage Free Brown Eggs Raley's Organic Large Cage Free Brown Eggs Simple Truth Medium & Large Brown Cage Free Eggs Sun Harvest Organic Cage Free Large Brown Eggs Sunnyside Large Brown Cage Free Eggs The eggs sold were distributed in fiber or plastic cartons with the plant code number P-6562 or CA5330. The CDC advises what you should do if you have a carton of recalled eggs in your home or business: What You Should Do: Do not eat any recalled eggs. Throw them away or return them to where you bought them. Wash items and surfaces that may have touched the recalled eggs using hot soapy water or a dishwasher. Call your healthcare provider if you have any severe Salmonella symptoms. What Businesses Should Do: Do not sell or serve recalled eggs. Wash and sanitize items and surfaces that may have come in contact with recalled eggs. About Salmonella: Most people infected with Salmonella develop diarrhea, fever, and stomach cramps 6 hours to 6 days after being exposed to the bacteria. The illness usually lasts 4 to 7 days, and most people recover without treatment. In some people, the illness may be so severe that the patient is hospitalized. Children younger than 5, adults 65 and older, and people with weakened immune systems are more likely to have severe illness. For more information, visit
